HNRNPA1 and amyotrophic lateral sclerosis: These findings suggest that PARP-1/2 inhibitors may have therapeutic potential for treating ALS.319 In the context of Drosophila, PARP inhibitors were shown to prevent TDP-43 accumulation and alleviate neurodegeneration.320 Furthermore, PARP silencing reduces neurotoxicity by preventing the condensate formation of hnRNPA1 and TDP-43 in a Drosophila model of ALS.321